Today Deutsche Bank Reconfirms a “Hold” Rating on GlaxoSmithKline PLC (LON:GSK) and a GBX 1500.00 Target Price


GlaxoSmithKline PLC (LON:GSK) Rating Reaffirmed

GlaxoSmithKline PLC (LON:GSK) just had their share rating of a ‘”Hold”‘ issued by research analysts at Deutsche Bank, who now has a GBX 1500.00 target PPS on the 64.92 billion GBP market cap company or a 12.44% upside potential. This key information was announced in a note on Monday, 21 December.

From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1477.54 with a 10.45% above today’s (GBX 1334) stock price. GlaxoSmithKline PLC was the topic of 98 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley maintained shares on December 18 with “Equalwt/In-Line” rating. Goldman Sachs maintained shares with “Buy” rating and GBX 1800 target share price in a report from a November 24. BNP Paribas maintained GSK stock in a recent report from December 9 with “Neutral” rating. J.P. Morgan maintained the rating on November 20. J.P. Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Liberum Capital maintained the stock with “Hold” rating in a report issued on a December 3.

The stock closed the day at GBX 1334 during the previous session. It is down 8.91% since May 22, 2015 and is downtrending. It has underperformed by 3.10% the S&P500.

Today Deutsche Bank Reconfirms a

GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 64.92 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.56 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”